drugset / Trial / NCT07461181
A Study to Evaluate the Safety, Tolerability, PK, PD, and Preliminary Efficacy of CS01 in Patients With Locally Advanced or Metastatic Solid Tumors
Phase 1/2
Active not recruiting
10 enrolled
Ruijin Hospital
Zhongshan Constimulus Bio Co., Ltd · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This is an investigator-initiated clinical trial evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of CS01 in patients with locally advanced or metastatic solid tumors.
Timeline
- Start
- 2024-12-30
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CS01 | Monoclonal antibody | 0.03 mg/kg | Intravenous |
| Subject | CS01 | Monoclonal antibody | 0.1 mg/kg | Intravenous |
| Subject | CS01 | Monoclonal antibody | 0.3 mg/kg | Intravenous |
| Subject | CS01 | Monoclonal antibody | 1 mg/kg | Intravenous |
Indications
No indication recorded.